Starling Oncology (STLNW) Long-Term Deferred Tax (2019 - 2020)
Starling Oncology's (STLNW) quarterly Long-Term Deferred Tax came in at $70000.0 in Q3 2020, up 79.49% quarter-over-quarter from $39000.0 in Q2 2020.
Powered by 
Analysis
Starling Oncology (STLNW) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends
Starling Oncology (STLNW) has reported Long-Term Deferred Tax for 2 consecutive years, with $70000.0 the latest figure, recorded in Q3 2020.
- For the quarter ending Q3 2020, Long-Term Deferred Tax changed N/A year-over-year to $70000.0; the trailing twelve-month figure through Sep 2020 stood at $70000.0 (changed N/A YoY), and the FY2019 full-year result was $300.0, changed N/A from the prior year.
- Long-Term Deferred Tax rose to $70000.0 in Q3 2020 per STLNW's latest filing, from $39000.0 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $70000.0 in Q3 2020 and bottomed at $300.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Davita | 11.90 Bn | 11.21 Bn | 1.16 Bn |
| 2 | RadNet | 5.52 Bn | 4.79 Bn | 88.08 Mn |
| 3 | Fresenius Medical Care AG | 4.79 Bn | 4.09 Bn | 1.52 Bn |
| 4 | Concentra Group Holdings Parent | 4.28 Bn | 4.12 Bn | 192.10 Mn |
| 5 | Privia Health | 2.57 Bn | 2.16 Bn | - |
| 6 | Pediatrix Medical | 2.15 Bn | 1.74 Bn | - |
| 7 | Progyny | 2.12 Bn | 1.89 Bn | 89.30 Mn |
| 8 | Surgery Partners | 1.82 Bn | 1.61 Bn | 622.10 Mn |
| 9 | U S Physical Therapy | 1.17 Bn | 1.14 Bn | 41.94 Mn |
| 10 | Starling Oncology | 4.13 Mn | -36.96 Mn | 27.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 70,000.00 |
| Jun 30, 2020 | 39,000.00 |
| Dec 31, 2019 | 300.00 |